RxDoctor Payments Data

Ann Ghory, MD

Allergy & Immunology · Cincinnati, OHNPI 1194759118

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 213 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AstraZeneca at 25.0% of the total. Reporting peaked in 2019 at $1,653 and has fallen 97.8% since, to $36 in 2024.

$4,085in general payments, 2019–2025

Across 213 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Sanofi$583
  • GSK$560
  • Regeneron Healthcare Solutions, Inc.$474
  • Genentech USA, Inc.$317
  • Covis Pharma GmbH$162
  • plus $967 from 17 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$4,00698%
  • Education$642%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,085 in reported general payments places this provider in the 60th percentile of 128 allergy & immunology providers in Ohio.

See all allergy & immunology providers in Ohio

Medicare billing

Part B allowed, 2024
$2,380
Medicare patients
31
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5012$141,682
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,671
Azelastine Hcl27$1,180
Albuterol Sulfate HfaAlbuterol Sulfate12$384
Montelukast Sodium39$223
Fluticasone Propionate11$154
BreynaBudesonide/Formoterol Fumarate13$0

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru$95$141,68212 claims
GSKTrelegy Ellipta$560$15,67116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 128 allergy & immunology providers in Ohio.

Other allergy & immunology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →